LNSR · LENSAR, Inc.
One customer — 14% of revenue (the three months ended March 31, 2026)
“For the three months ended March 31, 2026, one customer accounted for approximately 14% of our revenue.”
One customer — 12% of receivables (As of March 31, 2026)
“As of March 31, 2026, one customer accounted for approximately 12% of our accounts receivable, net.”
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 13, 2026TL;DR. LENSAR reported Q2 2026 total revenue of $16.5M (+18% YoY) with recurring revenue up 20% and procedure revenue up 23%, driven by 30% growth in the ALLY installed base to 215 systems and a 13-system backlog, while delivering its strongest Adjusted EBITDA to date of $3.6M and positive net income of $3.5M.
- + Q2 total revenue grew 18% YoY to $16.5M and recurring revenue grew 20% to $13.7M.
- + Procedure revenue grew 23% YoY to $10.2M on 13% procedure volume growth to 58,682.
- + ALLY installed base grew 30% YoY to 215 systems, with 10 placements in Q2 and a backlog of 13 ALLY systems.
- + Delivered strongest Adjusted EBITDA to date of $3.6M versus $(0.3)M in Q2 2025 and positive net income of $3.5M.
- + Management indicated the new ~52% gross margin level is sustainable as recurring revenue grows, versus prior 'high 40s' framing.
- − Cash, cash equivalents, and investments declined to $13.6M at June 30, 2026 from $18.0M at December 31, 2025.
- − Management expects operating expenses and income/EBITDA variability over the next several quarters as spending levels gradually expand for strategic commercial investments.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $3.6M | Q2 2026 | — |
| ALLY System Placements | 10 | Q2 2026 | — |
| EBITDA non-GAAP | $4.47M | Three months ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP Net income (loss) 3.54M
-171K Interest income
+878K Depreciation expense
+228K Amortization expense
= EBITDA 4.47M
|
|||
| Procedure volume | 58,682 | Q2 2026 | — |
| Recurring revenue % | 83% | Q2 2026 | — |
| Total ALLY Installed Base | 215 | Q2 2026 | — |
| Total Laser Installed Base | 445 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LNSR
this stock
LENSAR, Inc.
|
$85.02M | -42.6% | +9.2% | 5.5 | 2.8% |
|
ABT
Abbott Laboratories
|
$174.90B | -20.1% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -8.4% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -18.8% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -55.5% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LNSR | -3.1% | -22.3% | +10.4% | +1.2% | -42.7% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -4.3% | -22.9% | -1.1% | -0.4% | -56.3% |